ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma.
Clin Cancer Res.
2023 Jul 14;29(14):2651-2667. doi: 10.1158/1078-0432.CCR-21-3521. PubMed PMID:
36780194; PubMed Central PMCID:
PMC10363218.
Cancer aneuploidies are shaped primarily by effects on tumour fitness.
Nature.
2023 Jul;619(7971):793-800. doi: 10.1038/s41586-023-06266-3. Epub 2023 Jun 28. PubMed PMID:
37380777; PubMed Central PMCID:
PMC10529820.
Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics.
Neuro Oncol.
2023 Jan 5;25(1):199-210. doi: 10.1093/neuonc/noac132. PubMed PMID:
35604410; PubMed Central PMCID:
PMC9825351.
High-Resolution Profiling of Lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities.
Cancer Res.
2022 Nov 2;82(21):3917-3931. doi: 10.1158/0008-5472.CAN-22-0432. PubMed PMID:
36040373; PubMed Central PMCID:
PMC9718502.
Tangent normalization for somatic copy-number inference in cancer genome analysis.
Bioinformatics.
2022 Oct 14;38(20):4677-4686. doi: 10.1093/bioinformatics/btac586. PubMed PMID:
36040167; PubMed Central PMCID:
PMC9563697.
The genomic landscape of dysembryoplastic neuroepithelial tumours and a comprehensive analysis of recurrent cases.
Neuropathol Appl Neurobiol.
2022 Oct;48(6):e12834. doi: 10.1111/nan.12834. Epub 2022 Aug 9. PubMed PMID:
35836307; PubMed Central PMCID:
PMC9542977.
FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits.
Cancer Res.
2022 Sep 2;82(17):2980-3001. doi: 10.1158/0008-5472.CAN-22-0671. PubMed PMID:
35802025; PubMed Central PMCID:
PMC9437574.
Structural variations in cancer and the 3D genome.
Nat Rev Cancer.
2022 Sep;22(9):533-546. doi: 10.1038/s41568-022-00488-9. Epub 2022 Jun 28. Review. PubMed PMID:
35764888; PubMed Central PMCID:
PMC10423586.
Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma.
Nat Commun.
2022 Aug 16;13(1):4814. doi: 10.1038/s41467-022-32430-w. PubMed PMID:
35973991; PubMed Central PMCID:
PMC9381513.
Structural variants shape driver combinations and outcomes in pediatric high-grade glioma.
Nat Cancer.
2022 Aug;3(8):994-1011. doi: 10.1038/s43018-022-00403-z. Epub 2022 Jul 4. PubMed PMID:
35788723; PubMed Central PMCID:
PMC10365847.
Early EEG hyperexcitability is associated with decreased survival in newly diagnosed IDH-wildtype glioma.
J Neurooncol.
2022 Aug;159(1):211-218. doi: 10.1007/s11060-022-04059-8. Epub 2022 Jun 17. PubMed PMID:
35715666; PubMed Central PMCID:
PMC9329255.
Glioma progression is shaped by genetic evolution and microenvironment interactions.
Cell.
2022 Jun 9;185(12):2184-2199.e16. doi: 10.1016/j.cell.2022.04.038. Epub 2022 May 31. PubMed PMID:
35649412; PubMed Central PMCID:
PMC9189056.
Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.
J Neurooncol.
2022 May;158(1):111-116. doi: 10.1007/s11060-022-04016-5. Epub 2022 Apr 26. PubMed PMID:
35474499; PubMed Central PMCID:
PMC10276926.
DNA-based copy number analysis confirms genomic evolution of PDX models.
NPJ Precis Oncol.
2022 Apr 28;6(1):30. doi: 10.1038/s41698-022-00268-6. PubMed PMID:
35484194; PubMed Central PMCID:
PMC9050710.
PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation.
Nat Commun.
2022 Feb 1;13(1):604. doi: 10.1038/s41467-022-28198-8. PubMed PMID:
35105861; PubMed Central PMCID:
PMC8807747.
Rates and Patterns of Clonal Oncogenic Mutations in the Normal Human Brain.
Cancer Discov.
2022 Jan;12(1):172-185. doi: 10.1158/2159-8290.CD-21-0245. Epub 2021 Aug 13. PubMed PMID:
34389641; PubMed Central PMCID:
PMC8758513.
A predominant enhancer co-amplified with the SOX2 oncogene is necessary and sufficient for its expression in squamous cancer.
Nat Commun.
2021 Dec 8;12(1):7139. doi: 10.1038/s41467-021-27055-4. PubMed PMID:
34880227; PubMed Central PMCID:
PMC8654995.
Quantification of aneuploidy in targeted sequencing data using ASCETS.
Bioinformatics.
2021 Aug 25;37(16):2461-2463. doi: 10.1093/bioinformatics/btaa980. PubMed PMID:
33247715; PubMed Central PMCID:
PMC8388019.
Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway.
Cell Rep.
2021 Feb 23;34(8):108784. doi: 10.1016/j.celrep.2021.108784. PubMed PMID:
33626341; PubMed Central PMCID:
PMC8608252.
Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis.
Cell.
2020 Dec 10;183(6):1617-1633.e22. doi: 10.1016/j.cell.2020.11.012. Epub 2020 Nov 30. PubMed PMID:
33259802; PubMed Central PMCID:
PMC7791404.
CloneSifter: enrichment of rare clones from heterogeneous cell populations.
BMC Biol.
2020 Nov 24;18(1):177. doi: 10.1186/s12915-020-00911-3. PubMed PMID:
33234154; PubMed Central PMCID:
PMC7687773.
Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.
J Clin Oncol.
2020 Oct 10;38(29):3407-3417. doi: 10.1200/JCO.19.02983. Epub 2020 Jul 24. PubMed PMID:
32706640; PubMed Central PMCID:
PMC7527157.
Epigenomic programming in early fetal brain development.
Epigenomics.
2020 Jun;12(12):1053-1070. doi: 10.2217/epi-2019-0319. Epub 2020 Jul 17. PubMed PMID:
32677466; PubMed Central PMCID:
PMC7857341.
Cas9 activates the p53 pathway and selects for p53-inactivating mutations.
Nat Genet.
2020 Jul;52(7):662-668. doi: 10.1038/s41588-020-0623-4. Epub 2020 May 18. PubMed PMID:
32424350; PubMed Central PMCID:
PMC7343612.
Ancestry-specific predisposing germline variants in cancer.
Genome Med.
2020 May 29;12(1):51. doi: 10.1186/s13073-020-00744-3. PubMed PMID:
32471518; PubMed Central PMCID:
PMC7260738.
Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer.
Cancer Cell.
2020 May 11;37(5):639-654.e6. doi: 10.1016/j.ccell.2020.04.012. PubMed PMID:
32396860; PubMed Central PMCID:
PMC7328015.
Mechanisms and therapeutic implications of hypermutation in gliomas.
Nature.
2020 Apr;580(7804):517-523. doi: 10.1038/s41586-020-2209-9. Epub 2020 Apr 15. PubMed PMID:
32322066; PubMed Central PMCID:
PMC8235024.
WNT-Activated Medulloblastomas With Hybrid Molecular Subtypes.
JCO Precis Oncol.
2020;4. doi: 10.1200/PO.19.00332. eCollection 2020. PubMed PMID:
32923883; PubMed Central PMCID:
PMC7446405.
Analyses of non-coding somatic drivers in 2,658 cancer whole genomes.
Nature.
2020 Feb;578(7793):102-111. doi: 10.1038/s41586-020-1965-x. Epub 2020 Feb 5. PubMed PMID:
32025015; PubMed Central PMCID:
PMC7054214.
Patterns of somatic structural variation in human cancer genomes.
Nature.
2020 Feb;578(7793):112-121. doi: 10.1038/s41586-019-1913-9. Epub 2020 Feb 5. PubMed PMID:
32025012; PubMed Central PMCID:
PMC7025897.
TRIP13 regulates DNA repair pathway choice through REV7 conformational change.
Nat Cell Biol.
2020 Jan;22(1):87-96. doi: 10.1038/s41556-019-0442-y. Epub 2020 Jan 8. PubMed PMID:
31915374; PubMed Central PMCID:
PMC7336368.
The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients.
Neuro Oncol.
2019 Dec 17;21(12):1498-1508. doi: 10.1093/neuonc/noz119. Review. PubMed PMID:
31276167; PubMed Central PMCID:
PMC6917404.
Longitudinal molecular trajectories of diffuse glioma in adults.
Nature.
2019 Dec;576(7785):112-120. doi: 10.1038/s41586-019-1775-1. Epub 2019 Nov 20. PubMed PMID:
31748746; PubMed Central PMCID:
PMC6897368.
Sex is an important prognostic factor for glioblastoma but not for nonglioblastoma.
Neurooncol Pract.
2019 Dec;6(6):451-462. doi: 10.1093/nop/npz019. Epub 2019 May 18. PubMed PMID:
31832215; PubMed Central PMCID:
PMC6899055.
Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells.
Nat Commun.
2019 Aug 19;10(1):3731. doi: 10.1038/s41467-019-11493-2. PubMed PMID:
31427603; PubMed Central PMCID:
PMC6700116.
Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations.
Neuro Oncol.
2019 Aug 5;21(8):968-980. doi: 10.1093/neuonc/noz022. PubMed PMID:
30805642; PubMed Central PMCID:
PMC6682212.
Before and After: Comparison of Legacy and Harmonized TCGA Genomic Data Commons' Data.
Cell Syst.
2019 Jul 24;9(1):24-34.e10. doi: 10.1016/j.cels.2019.06.006. PubMed PMID:
31344359; PubMed Central PMCID:
PMC6707074.
Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma.
Nat Commun.
2019 Jun 3;10(1):2400. doi: 10.1038/s41467-019-10307-9. PubMed PMID:
31160565; PubMed Central PMCID:
PMC6546744.
Tandem Affinity Purification and Mass Spectrometry (TAP-MS) for the Analysis of Protein Complexes.
Curr Protoc Protein Sci.
2019 Jun;96(1):e84. doi: 10.1002/cpps.84. Epub 2019 Feb 1. PubMed PMID:
30706993; PubMed Central PMCID:
PMC6579647.
An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival.
Neurooncol Adv.
2019 May-Dec;1(1):vdz007. doi: 10.1093/noajnl/vdz007. Epub 2019 May 30. PubMed PMID:
31608326; PubMed Central PMCID:
PMC6777501.
miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human glioblastoma.
Oncogene.
2019 Apr;38(16):2923-2936. doi: 10.1038/s41388-018-0601-9. Epub 2018 Dec 17. PubMed PMID:
30559405; PubMed Central PMCID:
PMC6497411.
Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma.
JCO Precis Oncol.
2019;3. doi: 10.1200/PO.18.00071. eCollection 2019. PubMed PMID:
32914038; PubMed Central PMCID:
PMC7448806.
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
J Clin Oncol.
2019 Mar 20;37(9):741-750. doi: 10.1200/JCO.18.01207. Epub 2019 Feb 4. PubMed PMID:
30715997; PubMed Central PMCID:
PMC6553812.
Genomic evolution of cancer models: perils and opportunities.
Nat Rev Cancer.
2019 Feb;19(2):97-109. doi: 10.1038/s41568-018-0095-3. Review. PubMed PMID:
30578414; PubMed Central PMCID:
PMC6493335.
PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma.
Clin Cancer Res.
2019 Jan 1;25(1):334-345. doi: 10.1158/1078-0432.CCR-18-0452. Epub 2018 Nov 15. PubMed PMID:
30442683; PubMed Central PMCID:
PMC6384094.
Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling.
Cancer Cell.
2018 Dec 10;34(6):922-938.e7. doi: 10.1016/j.ccell.2018.11.005. PubMed PMID:
30537514; PubMed Central PMCID:
PMC6352909.
The chromatin accessibility landscape of primary human cancers.
Science.
2018 Oct 26;362(6413). doi: 10.1126/science.aav1898. PubMed PMID:
30361341; PubMed Central PMCID:
PMC6408149.
Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.
Clin Cancer Res.
2018 Sep 15;24(18):4416-4428. doi: 10.1158/1078-0432.CCR-17-3649. Epub 2018 May 30. PubMed PMID:
29848573; PubMed Central PMCID:
PMC6139043.
Vemurafenib and cobimetinib overcome resistance to vemurafenib in BRAF-mutant ganglioglioma.
Neurology.
2018 Sep 11;91(11):523-525. doi: 10.1212/WNL.0000000000006171. Epub 2018 Aug 17. PubMed PMID:
30120137; PubMed Central PMCID:
PMC9694795.
Genetic and transcriptional evolution alters cancer cell line drug response.
Nature.
2018 Aug;560(7718):325-330. doi: 10.1038/s41586-018-0409-3. Epub 2018 Aug 8. PubMed PMID:
30089904; PubMed Central PMCID:
PMC6522222.
What would you like to do?